TransMedics, Inc.

In Rome for the day to participate in the Press Conference near the Italian Parliament to support the national reimbursement initiative for the OCS technology in Italy. We are grateful to the Italian patient organization and the Italian heart, lung and liver transplant academic experts who are leading this important initiative. The future looks promising for OCS, not just in Italy but also across Europe in the upcoming years. The collaborative efforts of various stakeholders pave the way for advancements in medical technology and patient care. OCS NOP in EU will become a reality very soon! #OCS #Transmedics #transplants #EUOCSNOP

This week, over 175 transplant experts gathered for the transplant leadership forum focusing on lung, heart, and liver transplants. The event highlighted the Next-Gen OCS lung and heart clinical initiatives, along with an update on the first 4,500 OCS liver transplants in the US. The engagement and participation of clinical experts were greatly appreciated. Exciting advancements are on the horizon for 2025, as the Next-OCS is set to revolutionize the lung and heart transplant market. Stay tuned for the incredible developments ahead! OCS- Beyond Preservation! #transmedics #beyondpreservation #OCS

TMDX was featured at Investors Business Daily. We are honored and humbled by our success to-date. We must remember that we are still early and we have a long runway of growth ahead to maximize the availability of healthy donor organs to help patients in need for organ transplants globally! TMDX team is working tirelessly to achieve this vision!

Our industry partners make the #ISHLT2024 Annual Meeting possible. Today, we recognize Pinnacle-level Supporter TransMedics, Inc. for their support of the Annual Meeting. You can see TransMedics on-site in Prague at booth 13.

Here is another real world positive impact of TransMedics’ OCS Liver and NOP to increase utilization of DCD livers for transplantation. In 2023, the US liver transplant volume grew by 12% primarily because of this impact. Again, TMDX NOP can do more to continue to drive additional growth in liver, heart and lung transplants in the US! We are grateful for donor families, our transplant centers who entrusted to procure and manage OCS perfusion for them and our world-class TMDX Team who is making this transformation a clinical reality!

The OCS Heart and NOP were used for ~70% of the DCD heart transplanted in the US in 2023, resulting in the lion’s share of the 13% growth of the national heart transplant volume in 2023! We can do more! Grateful to donor families, our clinical users and our world-class NOP clinical and logistics teams!

TMDX world-class NOP clinical and aviation teams coming together to deliver precious donor organs to patients in need across the US! Keep up the great work Team TMDX!